Syndrome News and Research

RSS

SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval from the Chinese State Food and Drug Administration ("SFDA) for the production of generic Omeprazole Sodium injections.

19 Aug 2009

Novel genome-analysis strategy to speed search for gene-disease links

University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. By saving time and lowering expenses, the approach makes it feasible for scientists to search for disease-causing genes in people with the same inherited disorder but without any family ties to each other.

18 Aug 2009

Shire starts two adult ADHD outreach programs

Shire plc today announced two initiatives reinforcing their commitment to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral disorder that affects an estimated 10 million adults across the country.

18 Aug 2009

Infant sleep environments depicted in magazines targeted to women of childbearing age

More than one third of photos in women's magazines depicted babies in unsafe sleep positions, according to a new study in Pediatrics. Additionally, the study found that two-thirds of sleep environments depicted in these magazines were also unsafe.

17 Aug 2009

When cell death goes wrong - scientists gain new insights

Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die. The work may help scientists to eventually develop new treatments for the many common diseases and conditions which occur when cell death goes wrong.

13 Aug 2009

Discovery of first gene involved in regulating the optimal length of human sleep

Scientists have discovered the first gene involved in regulating the optimal length of human sleep, offering a window into a key aspect of slumber, an enigmatic phenomenon that is critical to human physical and mental health.

13 Aug 2009

Study looks at imipramine in the treatment of irritable bowel syndrome

IBS remains a common intestinal disorder causing significant discomfort and poor quality of life in patients who have the diagnosis. TCAs have been shown to improve abdominal pain in patients with IBS; however, there is insufficient evidence of global symptom relief. The search for an optimal treatment to improve symptoms and quality of life in IBS remains ongoing.

12 Aug 2009

Cannabis Science reports on future plans for cannabis drug trials

Cannabis Science, Inc. (OTCBB: CBIS) has announced that it has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials.

12 Aug 2009

New insights into identifying children at risk for autoimmune brain disorders

A new study by researchers at Columbia University Mailman School of Public Health's Center for Infection and Immunity indicates that pediatric obsessive-compulsive disorder (OCD), Tourette syndrome and/or tic disorder may develop from an inappropriate immune response to the bacteria causing common throat infections.

11 Aug 2009

Discovery of a genetic mutation underlying late-onset Leigh syndrome

Researchers at the Montreal Neurological Institute and Hospital (The Neuro), McGill University have discovered a genetic mutation underlying late-onset Leigh syndrome, a rare inherited metabolic disorder characterized by the degeneration of the central nervous system.

11 Aug 2009

AIDS Research Center earns $7.5 million grant renewal

The University of Alabama at Birmingham (UAB) Center for AIDS Research (CFAR) has won a $7.5 million grant to continue its work in the research, prevention and treatment of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS).

11 Aug 2009

Gene Signal publishes phase I data on GS-101 for diseases of the eye

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced publication of data from a phase I study demonstrating that the antisense oligonucleotide GS-101 (eye drops) is safe, with no signs of intolerability following administration to healthy volunteers.

11 Aug 2009

Detection is the key to preventing the sudden death of young athletes

Few things stun a community more than when a seemingly healthy high school or collegiate athlete suddenly dies during practice or in competition from a hidden heart disorder.

11 Aug 2009

Secretary Sebelius announces Senate confirmation of Dr. Francis Collins as Director of NIH

HHS Secretary Kathleen Sebelius announced today that the United States Senate unanimously confirmed Dr. Francis Collins as the next Director of the National Institutes of Health.

10 Aug 2009

Chemists rationally design inhibitors against an RNA molecule that causes myotonic muscular dystrophy

Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.

9 Aug 2009

Transcranial MR-guided focused ultrasound for brain disorders a step closer

A team of researchers working at the MR-Center of the University Children's Hospital in Zürich has completed a pilot study using transcranial MR-guided focused ultrasound to treat 10 patients with neuropathic pain.

9 Aug 2009

Scientists discover link between mutations in INPP5E gene and ciliopathies

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, have discovered a connection between mutations in the INPP5E gene and ciliopathies. Their findings, which may lead to new therapies for these diseases, will appear in the online edition of Nature Genetics on August 9.

9 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

New insight into human ciliopathy

In the September 1st issue of G&D, Dr. Karen Oegema (UCSD) and colleagues identify the molecular basis of the lethal developmental disorder, hydrolethalus syndrome, and reveal that hydrolethalus syndrome actually belongs to the emerging class of human ciliopathy diseases.

4 Aug 2009

Emergency physicians should trust their judgment on chest pain symptoms

Their research suggests that emergency physicians should counsel with other physicians against discharge when they feel strongly about a patient for whom there is no compelling data, other than our evaluation and judgment, Chandra said.

4 Aug 2009